Thermo Fisher posts 10% growth in Q2

By LabPulse.com staff writers

July 22, 2020 -- Thermo Fisher Scientific reported financial results for the second quarter (end-June 27), noting 10% revenue growth.

For the second quarter of 2020, Thermo Fisher reported revenue growth of 10% to reach $6.92 billion, compared with $6.32 billion in the same quarter of 2019.

Compared with revenue in the first quarter of 2020 ($6.23 billion), ending on March 28, the company had revenue growth of 11% in the most recent quarter.

The company reported $1.3 billion of COVID-19-related revenue, and Thermo Fisher attributed much of the success in the second quarter to quickly mobilizing resources to support global COVID-19 responses.

Thermo Fisher expands COVID-19 therapies, vaccines
Thermo Fisher Scientific is expanding the development and production of COVID-19 vaccines, therapies, and additional treatments.
Thermo Fisher increases Qiagen acquisition offer
Thermo Fisher Scientific and Qiagen have amended their acquisition agreement with an increase from the original offer price of 39 euros ($44.61 U.S.)...
PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.
COVID-19 powers $5B in molecular diagnostics market growth
The worldwide demand for COVID-19 tests has materialized rapidly from nothing and is on course to become a multibillion-dollar market in 2020, writes...
Quest overall testing volume, revenue decline
Quest Diagnostics reported an 18% decline in overall test volume as part of a look at its preliminary financial results from the second quarter and reported...

Copyright © 2020 LabPulse.com

Last Updated np 7/23/2020 4:27:49 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current